Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Juvenile Diabetes Research Foundation | OTHER |
| University of Minnesota | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this extension study is to continue to follow the participants who completed the CLVer RCT for up to 3 additional years. The goal for Cohort A is to evaluate the longer-term effects of verapamil on preservation of β-cell function as measured by C-peptide levels obtained during a mixed meal tolerance test (MMTT). For both Cohorts A and B, the goal is to determine if the high degree of glycemic control achieved during CLVer with HCL can be maintained once the intensive engagement of the study team is discontinued. At the completion of the RCT, study treatments end. Thus, during the extension study, diabetes management is performed as part of usual care and there is no study treatment.
Participants who complete the CLVer RCT will be eligible to enroll in the CLVer Extension Study. Informed consent and assent, when applicable, will be obtained. Participants will be contacted every 3 months at which time continuous glucose monitoring (CGM) data will be obtained if a CGM device is being used and medical history (including recent point-of-care or local laboratory HbA1c values) will be reviewed; a usual care visit performed by study staff may be considered a study contact. A study visit will occur yearly to update the diabetes and medical history, measure height and weight, determine Tanner staging, download CGM data if available, perform an MMTT, and obtain blood samples for central lab measurement of HbA1c and plasma for storage if consented. Other than the central lab samples, there are no study-specific procedures or data collection that would not be performed as part of standard care.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort A | Participants with body weight ≥30 kg (Cohort A) were randomly assigned in a factorial design during the RCT to (1) HCL plus intensive diabetes management or usual care with no HCL and (2) verapamil or placebo. No interventions were administered during the observational extension. | ||
| Cohort B | Participants with body weight <30 kg (Cohort B) were randomly assigned during the RCT 2:1 in a parallel group design to HCL plus intensive diabetes management or to usual care with no HCL. No interventions were administered during the observational extension. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| C-peptide | The primary outcome is the C-peptide measured during the MMTT annually. This is measured as the area under the stimulated C-peptide curve (AUC). AUC is computed using a trapezoidal rule, which is a weighted sum of the C-peptide values over the 120 min. Peak C-peptide also will be computed. | Randomization, 13, 26, 39 weeks, Year 1, Year 2, Year 3, Year 4 |
| Measure | Description | Time Frame |
|---|---|---|
| HbA1c | HbA1c outcomes, measured annually, will include the following:
| Randomization, 13, 26, 39 weeks, Year 1, Year 2, Year 3, Year 4 |
| CGM Metrics |
Not provided
Completed CLVer RCT 12 month visit and willing to join observational extension.
Not provided
Not provided
Participants who complete the CLVer RCT 12 month visit. RCT participants were youth aged 7-<18 years at RCT screening with newly diagnosed stage 3 type 1 diabetes.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Antoinette Moran, MD | University of Minnesota | Study Chair |
| Gregory Forlenza, MD | Barbara Davis Center | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94304 | United States | ||
| Barbara Davis Center |
Not provided
Not provided
Not provided
Not provided
CGM metrics will be computed for each time point of data collection. CGM-derived indices will be computed for 24 hours, daytime (6AM to midnight) and nighttime (midnight to 6AM). The Statistical Analysis Plan (SAP) will describe how CGM derived indices will be calculated. The following metrics will be computed:
| 6, 13, 26, 39 weeks, Year 1, Year 2, Year 3, Year 4 |
| Severe hypoglycemia episodes | Frequency of episodes of severe hypoglycemia by cohort group. | Year 4 |
| Diabetic ketoacidosis events | Frequency of episodes of diabetic ketoacidosis by cohort group. | Year 4 |
| Hospitalizations | Frequency of hospitalizations by cohort group. | Year 4 |
| Aurora |
| Colorado |
| 80045 |
| United States |
| Yale University | New Haven | Connecticut | 06511 | United States |
| Indiana University | Indianapolis | Indiana | 46202 | United States |
| University of Minnesota | Minneapolis | Minnesota | 55455 | United States |
| Children's Mercy Hospital | Kansas City | Missouri | 64111 | United States |